Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes

• Main Authors: Xingcheng Yang (Author), Lijun Jiang (Author), Xiaoying Zhang (Author), Juan Peng (Author), Hu Qian (Author), Lifang Huang (Author), Shaolong He (Author), Zhiqiong Wang (Author), Liting Chen (Author), Yicheng Zhang (Author), Ling Ma (Author), Yuan Chen (Author), Jia Wei (Author)
• Format: Book
• Published: BMC, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract The role of the compromised immune microenvironment, including immune checkpoints, in myelodysplastic syndromes (MDS) has been identified as critical This study aimed to investigate the expression patterns of immune checkpoints, particularly soluble PD-1/PD-L1 (sPD-1/sPD-L1) as well as PD-1...